BioSpace News Archive

VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the Company has exercised its option to acquire from Pherin Pharmaceuticals, Inc.

BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced positive top line Phase 2 data from its Study 106 evaluating Plinabulin in combination with Neulasta

PulsePoint, the leading global authority in programmatic health technology, is set to host their inaugural Digital Health Forum on Radical Health Personalization: Where Medicine, Machine Learning and Media Converge.

Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with sevelamer, the current standard-of-care phosphate binder treatment for hyperphosphatemia, or elevated serum phosphorus.

SEngine Precision Medicine, a biotech startup delivering on the promise of precision oncology through functional genomics, today welcomed Dr. Leland (Lee) Hartwell to the SEngine Precision Medicine Board of Directors.

Autosomal dominant polycystic kidney disease (ADPKD) is a devastating rare genetic kidney condition that leads to the growth of numerous cysts in the kidneys.

Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced its Phase 3 study of UX007 in patients with glucose transporter type-1 deficiency syndrome

Hamamatsu Photonics has recently developed their smallest grating spectrometer, the SMD series mini-spectrometer C14384MA, offering high near-infrared sensitivity, compact size, light weight and low cost.

SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced long-term, 24-month follow up data from its proof-of-concept study that support the continued clinical development of its proprietary bioelectronic device to treat patients with rheumatoid arthritis (RA)

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer.